Epredia’s E1000 Dx Digital Pathology Solution Wins 2025 International Scanner Benchmark Awards from the Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA)

September 29, 2025

RUNCORN, United Kingdom--(BUSINESS WIRE)--The Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA), an international organization that advances the use of validated AI solutions in clinical practice, has announced that Epredia, a global leader in precision cancer diagnostics, has won three categories in the 2025 International Scanner Benchmark (ISB) for Epredia’s E1000 Dx Digital Pathology Solution. The ISB recognizes excellence in quality, throughput, and design of digital slide scanning technology for pathology.

The E1000 Dx consists of a high-speed, automated, whole-slide imaging digital scanner with medical grade viewer and advanced image management and viewer software that creates high-resolution digital images of up to 1,500 tissue samples daily. The E1000 Dx is designed to maximize laboratory throughput and efficiency with technology advancements in sample detection and quality control procedures, which has the potential to make diagnostics more efficient and accurate.

EMPAIA supports regulatory, legal, technical, and organizational pathways to the adoption of validated and certified AI solutions. Through the ISB, EMPAIA seeks to identify the pathology industry’s top image-based diagnostics technologies, which provide detailed digital images that are critical inputs for potential future AI-powered diagnostics.

Epredia’s E1000 Dx won the 2025 ISB in the categories of Quality for digital images at 20x magnification, and Quality and High Throughput for digital images at 40x magnification, the highest level of magnification tested. The honors were based on a comprehensive and objective scanner evaluation, performed on samples from a variety of laboratories across Europe and reviewed by a panel of pathologists. Winners were awarded at the 37th European Congress of Pathology in Vienna, Austria, in September.

Epredia’s E1000 Dx builds on technology originally developed by 3DHISTECH, a leading pathology and diagnostics company and close commercial partner of Epredia. 3DHISTECH also received top honors in the ISB for its Pannoramic 480 Dx digital slide scanner, in the categories of High Throughput for digital images at 20x magnification and Technical capabilities, as well as being recognized with the prestigious Innovator 2025 Award. Epredia is a distributor of the full 3DHISTECH digital pathology portfolio including the Pannoramic 480 Dx.

Steven Lynum, President of Epredia, said, "Digital pathology is the future of cancer diagnostics. As pathology laboratories face greater pressure to speed up processes and reduce costs, we are deeply honored that EMPAIA has recognized the E1000 Dx as a leader in both high throughput and quality. AI holds tremendous potential to enhance the way conditions like cancer are diagnosed and ultimately treated, but AI is only as powerful as the images available to analyze. We look forward to Epredia and 3DHISTECH solutions helping laboratories maximize their digital pathology investment today as well as the potential of this technology to support AI-powered diagnostics in the future."

Eprediaについて

Eprediaは解剖学的病理学分野におけるグローバルリーダーであり、精密がん診断と組織診断のための包括的なソリューションを提供しています。Erie Scientific、Menzel-Gläser、Microm、Shandon、Richard-Allan Scientificなどの主要ブランドを擁し、顕微鏡スライド、器具、消耗品などのポートフォリオを提供しています。Eprediaは2019年にPHC HoldingsによるThermo Fisher Scientific’のAnatomical Pathology事業の買収を受けて設立された。Eprediaは米国、英国、ドイツ、スイス、中国の主要拠点で事業を展開しており、総従業員数は約1,200人である。Eprediaは、世界中の患者のためにがん診断を強化することにより、生命を向上させるという使命の達成に全力を尽くしています。Eprediaとその製品に関する詳しい情報は、www.epredia.com.

をご覧ください。

PHCホールディングス株式会社について（PHCグループ）

PHCホールディングス株式会社（東証6523）は、人々の生活に良い影響を与え、改善するヘルスケアソリューションを通じて、社会の健康に貢献することを使命とするグローバルヘルスケア企業です。その子会社（PHCグループと総称）には、PHCコーポレーション、Epredia、Ascensia Diabetes Care、LSI Medience Corporation、Mediford、Wemexがある。これらの企業は、糖尿病管理、ヘルスケアソリューション、ライフサイエンス、診断に関わるソリューションの開発、製造、販売、サービスを行っている。PHC Group’の2022年度の連結売上高は3,564億円で、125カ国以上で製品とサービスをグローバルに販売しています。
www.phchd.com

PHCグループ’の2022年度の連結売上高は3,564億円で、125カ国以上で製品とサービスをグローバルに販売しています。

詳細については、以下までお問い合わせください。

Julia Cottrill
PHCグループ・コーポレート・コミュニケーション
Email：julia.cottrill@phchd.com